ATE398136T1 - Therapeutika und diagnostika, die die zelluläre ansprechbarkeit auf cytokine regulieren - Google Patents

Therapeutika und diagnostika, die die zelluläre ansprechbarkeit auf cytokine regulieren

Info

Publication number
ATE398136T1
ATE398136T1 AT97909070T AT97909070T ATE398136T1 AT E398136 T1 ATE398136 T1 AT E398136T1 AT 97909070 T AT97909070 T AT 97909070T AT 97909070 T AT97909070 T AT 97909070T AT E398136 T1 ATE398136 T1 AT E398136T1
Authority
AT
Austria
Prior art keywords
therapeutic
cytokine
diagnostics
signal transduction
present
Prior art date
Application number
AT97909070T
Other languages
English (en)
Inventor
Douglas Hilton
Warren Alexander
Elizabeth Viney
Tracy Willson
Rachael Richardson
Robyn Starr
Sandra Nicholson
Donald Metcalf
Nicos Nicola
Original Assignee
Inst Medical W & E Hall
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO3384A external-priority patent/AUPO338496A0/en
Priority claimed from AUPO5117A external-priority patent/AUPO511797A0/en
Application filed by Inst Medical W & E Hall filed Critical Inst Medical W & E Hall
Application granted granted Critical
Publication of ATE398136T1 publication Critical patent/ATE398136T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT97909070T 1996-11-01 1997-10-31 Therapeutika und diagnostika, die die zelluläre ansprechbarkeit auf cytokine regulieren ATE398136T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPO3384A AUPO338496A0 (en) 1996-11-01 1996-11-01 Therapeutic and diagnostic agents
AUPO5117A AUPO511797A0 (en) 1997-02-14 1997-02-14 Therapeutic and diagnostic agents-II

Publications (1)

Publication Number Publication Date
ATE398136T1 true ATE398136T1 (de) 2008-07-15

Family

ID=25645307

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97909070T ATE398136T1 (de) 1996-11-01 1997-10-31 Therapeutika und diagnostika, die die zelluläre ansprechbarkeit auf cytokine regulieren

Country Status (13)

Country Link
US (1) US20080166730A1 (de)
EP (2) EP1975234A2 (de)
JP (2) JP2001502183A (de)
KR (2) KR20000053017A (de)
CN (2) CN1253565A (de)
AT (1) ATE398136T1 (de)
CA (1) CA2270171A1 (de)
DE (1) DE69738767D1 (de)
DK (1) DK0948522T3 (de)
ES (1) ES2308785T3 (de)
GB (1) GB2331753A (de)
NO (1) NO992116L (de)
WO (1) WO1998020023A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495518B1 (en) 1994-06-13 2002-12-17 Vanderbilt University Method for importing biologically active molecules into cells
JPH11103867A (ja) * 1997-05-07 1999-04-20 Smithkline Beecham Corp Ｅｐｏ一次応答遺伝子１、ｅｐｒｇ１
WO1999003994A1 (en) * 1997-07-18 1999-01-28 Schering Corporation Suppressors of cytokine signaling socs16; related reagents
EP0970215A1 (de) * 1997-11-03 2000-01-12 Incyte Pharmaceuticals, Inc. Cytokinsignal-suppressor
EP1053007A2 (de) * 1998-02-11 2000-11-22 Beth Israel Deaconess Medical Center Methoden und zusammensetzungen zur modulierung der leptinaktivität
EP0953636A3 (de) 1998-03-23 2000-03-29 Smithkline Beecham Plc Cytokin-Signal Regulator
WO1999049032A1 (en) * 1998-03-23 1999-09-30 Smithkline Beecham Plc Suppressors of cytokine signalling
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
EP1082426A2 (de) * 1998-05-28 2001-03-14 Incyte Pharmaceuticals, Inc. Menschliche socs proteine
SE9803398D0 (sv) * 1998-10-06 1998-10-06 Sahltech Ab "New use"
WO2000037636A1 (en) * 1998-12-21 2000-06-29 The Walter And Eliza Hall Institute Of Medical Research Socs-box containing peptides
AU4651900A (en) * 1999-04-20 2000-11-02 Beth Israel Deaconess Medical Center Methods and compositions for modulating ciliary neurotrophic factor activity
US6541244B1 (en) 1999-06-07 2003-04-01 Cedars-Sinai Medical Center Suppressor of cytokine signaling (SOCS)-3 promoter and methods for its use in genetic therapy in humans
AU784277B2 (en) * 1999-11-16 2006-03-02 Walter And Eliza Hall Institute Of Medical Research, The An animal model for studying hormone signalling and method of modulating the signalling
DE60038977D1 (de) * 1999-11-16 2008-07-03 Inst Medical W & E Hall Tiermodell für hormonsignalstudien und verfahren zum verändern der signalübertragung
AU2001251612A1 (en) * 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
US20040072752A1 (en) * 2000-10-09 2004-04-15 Andrew Nash Modulating cytokine or hormone signalling in an animal comprising up-regulating the expression of socs sequence in the animal
GB2373502A (en) * 2000-11-08 2002-09-25 Smithkline Beecham Corp Suppressor of cytokine signalling 4 (SOCS4)
AU2002243250A1 (en) * 2000-12-14 2002-07-24 Pharmacia And Upjohn Company Socs (suppressor of cytokine signaling)
AUPR556601A0 (en) * 2001-06-08 2001-07-12 Ludwig Institute For Cancer Research Therapeutic and diagnostic molecules - II
JPWO2003072778A1 (ja) * 2002-02-27 2005-06-23 株式会社ジェノックス創薬研究所 アレルギー性疾患の検査方法
EP1734982A4 (de) * 2004-03-04 2009-08-05 Univ Vanderbilt In die zellen eindringende socs-polypeptide, die die zytokininduzierte signalleitung hemmen
JP2005312364A (ja) * 2004-04-28 2005-11-10 Mitsuo Itakura 糖尿病治療剤スクリーニング方法
US20090030179A1 (en) * 2005-02-15 2009-01-29 Toagosei Co., Ltd Antimicrobial peptide and use thereof
AU2010244972A1 (en) * 2009-05-08 2011-11-24 The Walter And Eliza Hall Institute Of Medical Research Modulation of inducible nitric oxide (iNOS) binding to SPRY domain-containing SOCS-box peptides (SSB)
KR101124622B1 (ko) * 2009-10-26 2012-03-19 한국생명공학연구원 Ｓｏｃｓ２ 유전자의 발현을 조절하여 자연 살해 세포를 활성화시키는 방법
EP3827838B1 (de) * 2015-12-16 2023-06-07 The Walter and Eliza Hall Institute of Medical Research Hemmung von cytokininduziertem sh2-protein in nk-zellen

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4420782C1 (de) * 1994-06-15 1995-08-17 Fluegge Ulf Ingo Prof Dr DNA-Sequenz, kodierend einen 2-Oxoglutarat/Malat-Translokator, Plasmide, Bakterien, Hefen und Pflanzen enthaltend diesen Transporter
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
JPH07291996A (ja) * 1994-03-01 1995-11-07 Yuu Honshiyo ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物
EP0832117A1 (de) * 1995-06-05 1998-04-01 The Trustees Of Dartmouth College Genexpression, stimuliert durch liganden
AU4723797A (en) * 1997-01-10 1998-08-03 Tadamitsu Kishimoto Novel stat function-regulatory protein
WO1999003994A1 (en) * 1997-07-18 1999-01-28 Schering Corporation Suppressors of cytokine signaling socs16; related reagents

Also Published As

Publication number Publication date
EP0948522B1 (de) 2008-06-11
WO1998020023A1 (en) 1998-05-14
KR20060053007A (ko) 2006-05-19
KR100719080B1 (ko) 2007-05-16
ES2308785T3 (es) 2008-12-01
KR20000053017A (ko) 2000-08-25
EP0948522A4 (de) 2001-09-19
CA2270171A1 (en) 1998-05-14
GB9905020D0 (en) 1999-04-28
EP1975234A2 (de) 2008-10-01
GB2331753A (en) 1999-06-02
CN101280305A (zh) 2008-10-08
EP0948522A1 (de) 1999-10-13
NO992116L (no) 1999-06-29
US20080166730A1 (en) 2008-07-10
JP2009060903A (ja) 2009-03-26
DK0948522T3 (da) 2008-09-22
CN1253565A (zh) 2000-05-17
JP2001502183A (ja) 2001-02-20
DE69738767D1 (de) 2008-07-24
NO992116D0 (no) 1999-04-30

Similar Documents

Publication Publication Date Title
ATE398136T1 (de) Therapeutika und diagnostika, die die zelluläre ansprechbarkeit auf cytokine regulieren
ATE32730T1 (de) Indikatormarkierte konjugate von metallothionein und zielsuchenden, biologisch aktiven molekuelen.
DK0960127T3 (da) Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf
ATE319823T1 (de) Bmp-12, bmp-13 und diese enthaltende sehne- induzierende zusammensetzungen
DE69435218D1 (de) Regulation der Genexpression von bcl-2
CY1105836T1 (el) 12, 13-τροποποιημενα παραγωγα εποθιλονης
DE60035032D1 (de) Verwendung von pioglitazone zur verbesserung der ketose und der azidose
DE69729796D1 (de) Verwendung von synergistischen zusammensetzungen von il-12 und ifn-alpha für die behandlung von infektiösen krankheiten
EP0575054A3 (de) Protein-C-Derivate.
GEP20043349B (en) Methods of Controlling Cutworm Pests
DK0956351T3 (da) Tumornekrosefaktorbeslægtet ligand
MY107573A (en) 2,4- and 2, 5-substituted pyridine-n-oxides, processes for their preparation and their use.
ATE227561T1 (de) Verwendung von alpha-alkylglucosiden und deren estern als antimikrobielle emulgatoren
DE69522671D1 (de) Elektroaktiver Werkstoff, seine Herstellung und seine Verwendung zur Herstellung von kathodischen Elementen
ATE435293T1 (de) Invertierte terminale repeats von aav, die für die transkription aktiviert sind, zur verwendung in rekombinanten aav-vektoren
TR28583A (tr) Arilpirrol insektisidal ve akarisidal unsurlarin suspansiyon konsantrat terkipleri.
ATE235915T1 (de) Behandlung von hämorrhagischem virusfieber mit protein c
ATE270469T1 (de) Begrenzungsschaltung für einen analogen verstärker
ATE224201T1 (de) Verwendungen von alpha-lactalbumin zusammensetzungen
DE69327693D1 (de) Interferon-Alpha/Beta bindendes Protein, seine Herstellung und seine enthaltende pharmazeutische Zusammensetzungen
ATE93831T1 (de) Araliphatische aldehyde.
DE3787954D1 (de) Verwendung von 5-(Subst. Phenyl)- Oxazolidinonderivaten zur Behandlung von Depressionen.
ES2061775T3 (es) Derivados de estrobirulina, su obtencion y empleo.
ATE165594T1 (de) Triarylethylenderivate zur therapeutischen verwendung
ES8204252A1 (es) Una disposicion de etapa de salida en contrafase

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties